Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) unit, Shanghai Juntope Biopharmaceutical, will conduct clinical trials on the JT118 injection after obtaining the approval of China's National Medical Products Administration, according to a Thursday filing on the Shanghai bourse.
The Chinese biopharmaceutical company will test the vaccine's safety and efficiency as a prevention of the monkeypox virus infection.
The company's shares jumped less than 5% in recent trade.